VCYT rides on Afirma and Decipher growth with strong earnings beat and liquidity, but macro pressures and rising competition cloud its near-term outlook.
Findings from ancillary study of Phase 3 STAMPEDE trial reveal Decipher Prostate test is prognostic for clinical outcomes in men with high-risk non-metastatic and metastatic prostate cancer Data ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its market-leading Decipher Prostate Genomic Classifier is the ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that new data presented at the 2025 ASCO Genitourinary Cancers ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its Decipher Prostate Genomic Classifier is the only gene ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (VCYT) (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that 17 Decipher-focused abstracts will be presented at the ...
Findings from the first prospective validation trial for biomarker presented at ASTRO 2025 Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced that new data from the ...
Zacks.com on MSN
Veracyte Stock Surges 45.6% in a Year: What's Driving the Rally?
Veracyte VCYT shares have surged 45.6% in the past year, showing impressive momentum. It has significantly outperformed the ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc (VCYT). (Nasdaq: VCYT), a leading cancer diagnostics company, today announced new data that reinforce the ability of its Decipher Bladder ...
Zacks Investment Research on MSN
Veracyte (VCYT) down 15.4% since last earnings report: Can it rebound?
It has been about a month since the last earnings report for Veracyte (VCYT). Shares have lost about 15.4% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...
Jonathan Wygant, VP at Veracyte (NASDAQ:VCYT), executed a substantial insider sell on November 12, according to an SEC filing. What Happened: A Form 4 filing with the U.S. Securities and Exchange ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results